Imaging Correlates of Renal Cell Carcinoma Biological Features

Status Completed

Clinical Trial Summary

Clinical Trial Description

This pilot study is designed to evaluate imaging parameters indicative of underlying tumor biology. Patients with large renal masses (>3 cm, or at the discretion of the investigator) who are planning to undergo nephrectomy will be identified, and recruited to undergo a contrast-enhanced magnetic resonance-Fluorodeoxyglucose-positron emission tomography (MR-FDG-PET) scan. Samples collected from their tumor after it is removed will undergo a variety of laboratory tests, including biomarker assessments and genotyping. By examining primary renal masses via a combination of MR and FDG-PET functional imaging in concert with tissue based tests, areas of hypermetabolism and hypervascularization will be evaluated as features of HIF activation or tumor subtype. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01665703
Study type	Interventional
Source	UNC Lineberger Comprehensive Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	August 2012
Completion date	January 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04987203` - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma	Phase 3
Recruiting	`NCT06391879` - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed	`NCT02526017` - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers	Phase 1
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated	`NCT03655613` - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC	Phase 1/Phase 2
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Withdrawn	`NCT05418387` - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona	N/A
Recruiting	`NCT04623502` - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy	N/A
Completed	`NCT02853344` - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)	Phase 2
Terminated	`NCT04088500` - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma	Phase 2
Completed	`NCT05070637` - Circulating Tumor Cell Reducing No-touch Nephrectomy	N/A
Active, not recruiting	`NCT03634540` - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)	Phase 2
Not yet recruiting	`NCT06049030` - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Completed	`NCT01358721` - Phase I Biomarker Study (BMS-936558)	Phase 1
Active, not recruiting	`NCT04503148` - Anesthesia and Cancer Study: Renal Cell Carcinoma	N/A
Completed	`NCT02386826` - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme	Phase 1
Not yet recruiting	`NCT05808608` - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma	Phase 1/Phase 2
Withdrawn	`NCT03323710` - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma	Phase 2
Completed	`NCT03052504` - Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy